Rodolphe BOURRET

📢 Surgical complications: a hidden burden on healthcare capacity and hospital finances Thrilled to unveil our newest publication in #BMJ Surgery, Interventions, & Health Technologies, carried out with François-Xavier Ladant, Julien Hedou, Yann Parc, Morgan Rouprêt, Alain Sautet, Jalal Assouad, Pierre RUFAT, and all our co-authors! 🔎 Hidden Costs of Surgical Complications: A Retrospective Cohort Study. Surgical complications don’t just impact patient outcomes—they reduce the number of patients hospitals can treat and weaken hospital finances. Our study, conducted in four surgical departments across three Parisian university hospitals à Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP), analyzed 54,637 hospital stays between 2017 and 2023. We found that 17.8% of surgeries resulted in complications. Key Findings: ✅ Every 10% reduction in the length of hospital stay (LOS) allows 9% more patients to be treated. ✅ Surgical complications extend hospital stays by an average of 10.9 days, leading to fewer available beds for new admissions. ✅ This "bed-blocking" effect results in an opportunity cost of €27.5M to €37.7M in lost hospital revenue over the study period. 🚨 Why does this matter? At a time when hospitals are struggling with capacity constraints, reducing complications is not just about patient safety—it is a public health priority. Preventing complications would allow hospitals to treat more patients, reduce waiting times, and improve financial sustainability. 💡 Investing in quality improvement isn’t just good medicine... 🔗 Read the full paper: link in comments 📩 Let’s discuss! What policies or strategies do you think could help hospitals reduce complications and optimize patient flow? #PublicHealth #HospitalCapacity #PatientSafety #HealthPolicy #SurgicalOutcomes #BMJ #HealthcareEconomics #QualityImprovement #Surgery

128

8 commentaires

Alantra is pleased to announce that it has advised Affidea Group, a leading pan-European provider of specialist healthcare services including cancer care, advanced diagnostic imaging and community-based polyclinics, on the acquisition of Uroviva Group, Switzerland’s foremost urology network, from German Equity Partners IV, a fund managed by independent German investment company ECM Equity Capital Management, and Uroviva Group’s founding physicians. Christopher Jobst, Managing Director at Alantra, said: “We are pleased to have advised Affidea in this successful transaction. The partnership with Uroviva creates a highly complementary platform with a leading market position in Switzerland and we look forward to seeing what it achieves in its next phase of growth.” André Hüneburg, Director at Alantra, added: “Our team provided senior M&A advisory throughout the entire process, leveraging our deep expertise of the DACH healthcare services industry to provide Affidea with unique access to the sellers and navigate the transaction towards a successful outcome for both parties.” Marc-Andre Christinat, CEO of Affidea Switzerland said: “With Uroviva joining our network, we are not only doubling our footprint in the country but also creating a leading national platform for integrated oncology care. It is not just a strategic expansion, it’s a commitment to our patients, doctors and the communities we serve. We appreciated Alantra’s collaborative approach throughout the process, supporting a smooth and efficient transaction that sets the foundation for long-term value creation.” Razvan Predica, Chief Commercial Officer for Affidea Group, added: “This transaction reflects our continued focus on high-impact growth opportunities that align with Affidea’s strategy of building integrated, specialist care platforms across Europe. Alantra’s deep sector knowledge, strong execution capabilities and strategic input were key points in delivering a successful outcome on this important acquisition for us”. This transaction underscores Alantra’s expertise in the healthcare sector, building on the recent advisory of KIRKBI A/S on its investment in AMBOSS, Oakley Capital on the strategic combination of WINDSTAR MEDICAL GROUP and Merz Lifecare, and Trill Impact on its partnership with TT medic Group. Read more: https://lnkd.in/d9BjcbxH #Healthcare #FinancialAdvisory 

88

1 commentaire

🎥 Exclusive interview from #ESTRO25 We had the pleasure of speaking with Prof Pierre Blanchard, Editor-in-Chief of Radiotherapy and Oncology and co-chair of the Joint Green Journal – The Lancet Oncology: Top Clinical Trials session, which took place this morning at #ESTRO25. In this on-site interview, Prof Blanchard shares his insights on: ✅ The evolving role of scientific journals in the context of this year’s congress theme: “Transformative innovation through collaboration” ✅ Why cross-journal partnerships—like the joint session between Radiotherapy & Oncology and The Lancet Oncology—are vital for the scientific community ✅ His advice for young researchers who aspire to publish meaningful and impactful work in the field of radiation oncology. #ESTRO25 #Radiotherapy #OncologyResearch #ScientificPublishing #CancerCare #GreenJournal #YoungResearchers

70

The Luxembourg Institute of Health is proud to lead Clinnova, part of the National Centres of Excellence in Research (NCER) program funded by the Luxembourg National Research Fund (FNR). This initiative brings together the University of Luxembourg, the Centre Hospitalier de Luxembourg (CHL), and the Hôpitaux Robert Schuman, alongside partners from France, Germany, and Switzerland🌍 Clinnova uses AI and health data to improve care for patients with inflammatory bowel diseases (IBD), rheumatic diseases, and multiple sclerosis (MS). 🤖📊 Since 2024, Dr Spyridon Sofos, head of Clinnova-IBD, has been actively enrolling patients at the CHL. In April this year the first patient completed their one-year follow-up - an important milestone. 🔬 Clinnova is creating a federated digital medicine ecosystem in the heart of Europe. Learn more on the project's website: https://lnkd.in/e-YnqV8N

71

1 commentaire

Tribun Health is proud to announce that CENTRE HOSPITALIER DE VERSAILLES, the leading institution of GHT 78 Sud, has selected CaloPix® to power the transformation of its pathology department. This marks a significant milestone in the modernization of public healthcare services in France—driven by innovation, collaboration, and readiness for the integration of artificial intelligence. “We were impressed by the solution’s user-friendliness, performance, and the quality of support.” — Dr. Claire Glaser, Head of Pathology, Versailles Hospital Center “This choice reflects a shared commitment to more effective, collaborative, and patient-centered care.” — Jean-François POMEROL, CEO, Tribun Health 🔗 CaloPix® will support: - Primary diagnostics - Interdisciplinary collaboration - AI integration readiness - Interoperability across GHTs and expert networks 📢 Read more on Pathology News: https://lnkd.in/eTfgAc8R #DigitalPathology #AIinHealthcare #PrecisionDiagnostics #HealthcareInnovation #HealthTech #PublicHealth #GHT78Sud

37

1 commentaire

Prof. Dr. Benoît Guery, médecin chef Service des maladies infectieuses: “When considering the treatment of 𝐶𝑙𝑜𝑠𝑡𝑟𝑖𝑑𝑖𝑜𝑖𝑑𝑒𝑠 𝑑𝑖𝑓𝑓𝑖𝑐𝑖𝑙𝑒 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛, it is essential to balance the best therapeutic outcomes for individual patients with strategies that minimize recurrence and reduce transmission at the population level. The best approach combines individualized care with public health initiatives, ensuring effective treatment while mitigating the broader impacts of 𝐶. 𝑑𝑖𝑓𝑓𝑖𝑐𝑖𝑙𝑒 on the healthcare system.” Learn more about CDI during his presentation on the 25th of March: https://lnkd.in/dRfEG6ah  

30